Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency
Conditions
- Ornithine Transcarbamylase Deficiency
Interventions
- BIOLOGICAL: ARCT-810
- OTHER: Placebo
Sponsor
Arcturus Therapeutics, Inc.